Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2000 participants.

Also called NCT05918861

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 2,000 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05918861
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Canada, Puerto Rico (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05918861. Randomized; quadruple masking; primary purpose treatment. Start 2023-10-03 (actual); primary completion 2027-08 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
Acronym
dal-GenE-2
Condition
Acute Coronary Syndrome
Intervention (Drug)
Dalcetrapib
Intervention (Drug)
Placebo
Lead sponsor
DalCor Pharmaceuticals (class: industry)
Collaborator
The Montreal Health Innovations Coordinating Center (MHICC) (class: other)

Record details

Record id
cardio:ct-nct05918861
Content hash
a75d8b37d608573cd6c0265a72c0e9ac554bb0a79f6de611e85569cd418df3b0